Fatty liver disease (NAFLD / MASLD)

A condition in which too much fat builds up in the liver in people who do not drink heavy amounts of alcohol. It is now often called metabolic dysfunction-associated steatotic liver disease (MASLD) and used to be called nonalcoholic fatty liver disease (NAFLD). It usually has few or no symptoms. It is more likely in people with obesity, metabolic syndrome or type 2 diabetes.

Also called Fatty Liver Disease · MASLD · Metabolic dysfunction-associated steatotic liver disease · NAFLD · Nonalcoholic fatty liver disease

  • Condition
  • In this atlas

Overview

Technical summary

MeSH descriptor D065626 (Non-alcoholic Fatty Liver Disease) is recorded as a broad match, because MedlinePlus now uses the newer name MASLD and this atlas has not compared the two sets of criteria. MASH, formerly NASH, is the form with inflammation and liver damage. The evidence recorded here is descriptive.

Classification codes

  • MeSH 2026 D065626

Burden

  • Burden Evidence stage not applicable Certainty not assessed

    MedlinePlus says MASLD is the most common chronic (long-term) liver disease, because of increasing rates of obesity, type 2 diabetes and high cholesterol.

    Applies to Mixed recipients People with metabolic syndrome or fatty liver disease (MedlinePlus and NIDDK patient pages)

    Population, setting and follow-up
    • People with metabolic syndrome or steatotic (fatty) liver disease, as described by MedlinePlus, NIDDK and MeSH. The liver page says children can also get it.
    • Not stated; patient information pages
    • Not stated; United States federal health agencies
    • Mostly adults; the liver page says it is more common in middle-aged or older people although children can also get it
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (descriptive page)
    Certainty method
    Not assessed
    Limitations
    A statement on a patient-information page with no count, year or country. It names MASLD, the newer name; whether the same holds for the NAFLD heading in MeSH is not stated.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (1)
    1. Supports Steatotic Liver Disease | Fatty Liver Disease (MedlinePlus health topic)

      Webpage · U.S. National Library of Medicine (MedlinePlus) · Edition Page fetched 2026-10-30. The request to fattyliverdisease.html was answered with this page, whose own URL line reads steatoticliverdisease.html.

      Locator
      Summary, Who is more likely to develop steatotic liver disease?, para after list
      How it applies
      MedlinePlus on how common MASLD is.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      a6c075e913bfec6d9500517e7299f1bda46f3a206c4b67ed7865f3d1b807db5c
      Reuse basis
      MedlinePlus states that works produced by the federal government are not copyrighted, and lists summaries on health topic pages, medical test information and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.

Claims and evidence

Context People with metabolic syndrome or fatty liver disease (MedlinePlus and NIDDK patient pages)

Recipient
Mixed recipients
Population
People with metabolic syndrome or steatotic (fatty) liver disease, as described by MedlinePlus, NIDDK and MeSH. The liver page says children can also get it.
Care setting
Not stated; patient information pages
Geography
Not stated; United States federal health agencies
Life stage
Mostly adults; the liver page says it is more common in middle-aged or older people although children can also get it
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (descriptive page)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
Included
None stated
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    NIDDK says that certain health conditions and diseases, including obesity, metabolic syndrome and type 2 diabetes, make a person more likely to develop NAFLD.

    Applies to Mixed recipients People with metabolic syndrome or fatty liver disease (MedlinePlus and NIDDK patient pages)

    Certainty method
    Not assessed
    Limitations
    A patient-information page. It names conditions that make NAFLD more likely and gives no size for the risk. A patient-information or vocabulary source: it describes the condition and the direction of any risk. It gives no size for the risk, no time frame and no comparison group, and it is not clinical advice.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (1)
    1. Supports NIDDK: Nonalcoholic Fatty Liver Disease (NAFLD) & NASH

      Webpage · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health · Edition NIDDK page fetched 2026-10-30. The review date shown on the page itself was not recorded.

      Locator
      Symptoms & Causes
      How it applies
      NIDDK on conditions linked to NAFLD.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      8461101028cc8a6fe2a5ae378516742d7f0fe30750b3113ad14d005be7544519
      Reuse basis
      The NIDDK copyright page (fetched 2026-10-30, sha256 977bc7ff58fd3f8dc5059eaa6d2b535a44f6a296df9cd68d19202916a71c2126, hash only) says the majority of information on the NIDDK site is copyright free and can be freely downloaded and reproduced, with NIDDK acknowledged as the source, and warns of a few exceptions such as documents sponsored with private companies. The raw page is committed in the atlas repository.
  • Description Evidence stage not applicable Certainty not assessed

    MedlinePlus says steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in the liver, and that metabolic dysfunction-associated steatotic liver disease (MASLD) is the type that is not caused by heavy alcohol use and used to be called nonalcoholic fatty liver disease. NIDDK uses the older name and describes nonalcoholic fatty liver disease (NAFLD) as a condition in which fat builds up in the liver. MedlinePlus says MASLD usually has few or no symptoms. The MeSH scope note describes a fatty liver finding without excessive alcohol consumption.

    Applies to Mixed recipients People with metabolic syndrome or fatty liver disease (MedlinePlus and NIDDK patient pages)

    Certainty method
    Not assessed
    Limitations
    The MeSH heading and the NIDDK page use the older name NAFLD; the newer MedlinePlus page uses MASLD. This atlas does not compare the two sets of criteria. A patient-information or vocabulary source: it describes the condition and the direction of any risk. It gives no size for the risk, no time frame and no comparison group, and it is not clinical advice.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports MeSH scope note for descriptor D065626 (Non-alcoholic Fatty Liver Disease)

      Dataset · U.S. National Library of Medicine · Edition MeSH linked-data record of the preferred concept M0533561 of descriptor D065626, fetched 2026-10-30. The scope note is on this concept record, not on the descriptor record. · MeSH: M0533561

      Locator
      scopeNote.@value
      How it applies
      MeSH scope note for the descriptor.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      08a55f15b8346a30ee07fe8675338e274b7279f8e97c4a3b8adf974a336eee09
      Reuse basis
      The NLM web policies page (fetched 2026-10-30, sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
    2. Supports Steatotic Liver Disease | Fatty Liver Disease (MedlinePlus health topic)

      Webpage · U.S. National Library of Medicine (MedlinePlus) · Edition Page fetched 2026-10-30. The request to fattyliverdisease.html was answered with this page, whose own URL line reads steatoticliverdisease.html.

      Locator
      Summary, What is steatotic liver disease? and What is MASLD?
      How it applies
      MedlinePlus definitions and names.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      a6c075e913bfec6d9500517e7299f1bda46f3a206c4b67ed7865f3d1b807db5c
      Reuse basis
      MedlinePlus states that works produced by the federal government are not copyrighted, and lists summaries on health topic pages, medical test information and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
    3. Supports NIDDK: Nonalcoholic Fatty Liver Disease (NAFLD) & NASH

      Webpage · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health · Edition NIDDK page fetched 2026-10-30. The review date shown on the page itself was not recorded.

      Locator
      Definition & Facts
      How it applies
      NIDDK definition of NAFLD.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      8461101028cc8a6fe2a5ae378516742d7f0fe30750b3113ad14d005be7544519
      Reuse basis
      The NIDDK copyright page (fetched 2026-10-30, sha256 977bc7ff58fd3f8dc5059eaa6d2b535a44f6a296df9cd68d19202916a71c2126, hash only) says the majority of information on the NIDDK site is copyright free and can be freely downloaded and reproduced, with NIDDK acknowledged as the source, and warns of a few exceptions such as documents sponsored with private companies. The raw page is committed in the atlas repository.

Registry records

Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry trials 8

Record details

Record id
cardio:nafld
Content hash
31c1028b2ea258006ae95d9470eb08cd54ed40d999b389df88193635ff056bbb